The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Oslif Breezhaler

300 microgram(s) Inhalation Powder, Capsule

Novartis Europharm LimitedEU/1/09/586/6-10

Main Information

Trade NameOslif Breezhaler
Active SubstancesIndacaterol maleate
Strength300 microgram(s)
Dosage FormInhalation Powder, Capsule
Licence HolderNovartis Europharm Limited
Licence NumberEU/1/09/586/6-10

Group Information

ATC CodeR03AC Selective beta-2-adrenoreceptor agonists
R03AC18 indacaterol


Licence Issued30/11/2009
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back